A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Breastcancer Clinical Trial

Official title:

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03165955
• Other study ID #: KX-ORAX-007
• Secondary ID: U1111-1176-4228
• Status: Completed
• Phase: Phase 1
• Start date: May 9, 2017
• Est. completion date: November 22, 2018

Study information

• Verified date: March 2022
• Source: Athenex, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label, single-arm PK study in patients for whom paclitaxel treatment is indicated.

Description:

This is a multicenter, open-label, single-arm PK study in approximately 24 breast cancer patients for whom paclitaxel treatment is indicated. The study contains 3 periods: the Screening / Baseline Period, the Treatment Period, and the Follow-up Period. A Final Visit will occur within 7 days of the last dose of study treatment. If subjects achieve stable disease (SD), partial response (PR), or complete response (CR) at the end of the Treatment Period, they may continue Oraxol treatment in a separate extension study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: November 22, 2018
• Est. primary completion date: November 22, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed written informed consent

2. Women =18 years of age on day of consent

3. Breast cancer in patients for whom treatment with IV paclitaxel at 80 mg/m2 as monotherapy has been recommended by their oncologist

4. Measurable disease as per RECIST v1.1 criteria

5. Adequate hematological status as demonstrated by not requiring transfusion support or

granulocyte-colony stimulating factor (G-CSF) maintain:

• Absolute neutrophil count (ANC) =1.5 x 10^9/L
• Platelet count =100 x 10^9/L
• Hemoglobin (Hgb) =9 g/dL

6. Adequate liver function

• Total bilirubin of =1.5 mg/dL
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3 x upper limit of normal (ULN) or =5 x ULN if liver metastasis is present
• Alkaline phosphatase (ALP) =3 x ULN or =5 x ULN if bone metastasis is present
• Gamma glutamyl transferase (GGT) <10 x ULN

7. Adequate renal function as demonstrated by serum creatinine =1.5 x ULN

8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

9. Life expectancy of at least 3 months

10. Willing to fast for 6 hours before and 2 hours after Oraxol administration on all treatment days

11. Willing to abstain from alcohol consumption for 3 days before the first dose of study drug through the completion of the second inpatient PK sampling period

12. Willing to refrain from caffeine consumption for 12 hours before each inpatient dosing period through the completion of protocol-specified PK sampling for that week

13. Subjects must be postmenopausal (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of assigned study treatment.

14. Subjects who are of childbearing potential must have a negative serum pregnancy test at Screening and within 96 hours before dosing.

Exclusion Criteria:

1. Have not recovered to = Grade 1 toxicity from previous anticancer treatments or previous investigational products (IPs)

2. If previously treated with a taxane (paclitaxel or docetaxel) as part of anthracycline-based adjuvant chemotherapy or for metastatic disease, the subject relapsed less than 1 year following treatment

3. Subjects unable to swallow study medication in its intact form or have clinically significant malabsorption syndrome

4. Only site of metastatic disease is unmeasurable according to RECIST v1.1 criteria

5. Known CNS metastasis, including leptomeningeal involvement

6. Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer

7. Are currently receiving other medications intended for the treatment of their malignancy

8. Women who are pregnant or breastfeeding

9. Taking prohibited medications:

10. Use of warfarin. Subjects receiving warfarin who are otherwise eligible and who may be appropriately managed with low molecular weight heparin, in the opinion of the Investigator, may be enrolled in the study provided they are switched to low molecular weight heparin at least 7 days prior to receiving study treatment.

11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements

12. Known allergic reaction or intolerance to study medication components

13. Known allergic reaction or intolerance to contrast media

14. Subjects who, in the Investigator's opinion, are not suitable for participation in this study

Related Conditions & MeSH terms

• Breast Neoplasms
• Breastcancer

Intervention

Drug:
• Oraxol
HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules

Locations

Country	Name	City	State
Taiwan	China Medical University Hospital	Taichung
Taiwan	National Taiwan University Hospital	Taipei
Taiwan	Shuang Ho Hospital	Taipei
Taiwan	Taipei Medical University Hospital	Taipei
Taiwan	Taipei Veterans Generla Hospital	Taipei
Taiwan	Tri-Service General Hospital	Taipei

Sponsors (2)

Lead Sponsor	Collaborator
Athenex, Inc.	PharmaEssentia

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PK Parameters for paclitaxel_AUC (0-52)	PK parameters were summarized using the mean, SD	PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary	PK Parameters for paclitaxel_Cmax	PK parameters were summarized using the mean, SD	PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary	PK Parameters for paclitaxel_Ctrough(24)	PK parameters were summarized using the mean, SD	PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary	PK Parameters for paclitaxel_Ctrough(48)	PK parameters were summarized using the mean, SD	PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary	PK Parameters for paclitaxel_Cmax(0-24)	PK parameters were summarized using the mean, SD	PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary	PK Parameters for paclitaxel_Cmax(24-48)	PK parameters were summarized using the mean, SD	PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary	PK Parameters for paclitaxel_Cmax(48-52)	PK parameters were summarized using the mean, SD	PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary	PK Parameters for paclitaxel_tmax(0-24)	PK parameters were summarized using the median, minimum, maximum	PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary	PK Parameters for paclitaxel_tmax(24-48)	PK parameters were summarized using the median, minimum, maximum	PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary	PK Parameters for paclitaxel_tmax(48-52)	PK parameters were summarized using the median, minimum, maximum	PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Secondary	Safety of Oraxol in Breast Cancer Patients	Safety was assessed by evaluating treatment-emergent adverse events (TEAEs) including SAEs, laboratory evaluations (hematology, blood chemistry, and urinalysis), vital signs, physical examinations, and electrocardiograms (ECGs).	From enrollment through study completion, approximately 17 weeks
Secondary	Response Rate	Tumor response rate and 95% confidence interval (CI) were evaluated based on the number of subjects with any post-baseline CR or PR per RECIST 1.1 as assessed by the Investigator and the ICRRC.	From baseline through study completion, around 21 weeks
Secondary	Progression-free Survival	PFS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs.; The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation	From baseline through study completion, around 21 weeks
Secondary	Overall Survival	OS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs.; The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation	From baseline through study completion, around 21 weeks